In vitro activity of the aerosolized agents colistin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in southwestern Germany

被引:54
作者
Schülin, T [1 ]
机构
[1] Univ Freiburg, Dept Microbiol & Hyg, Freiburg, Germany
关键词
D O I
10.1093/jac/49.2.403
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Three hundred and eighty-five mucoid and non-mucoid strains of Pseudomonas aeruginosa isolated from 192 sputa from 57 adult cystic fibrosis patients were studied. Susceptibility testing using an agar dilution technique was performed for ceftazidime, ciprofloxacin, fosfomycin, meropenem and piperacillin, and the aerosolized agents colistin and tobramycin. Meropenem, ceftazidime and piperacillin were the most potent agents (susceptibility 86.2%, 84.2% and 84%, respectively). Tobramycin and colistin susceptibility rates were lower, but in light of higher intrabronchial concentrations of these drugs a greater percentage of strains might still be clinically susceptible. Only 46.2% and 41.8% of isolates were susceptible to ciprofloxacin and fosfomycin, respectively.
引用
收藏
页码:403 / 406
页数:4
相关论文
共 16 条
  • [1] Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis
    Burns, JL
    Van Dalfsen, JM
    Shawar, RM
    Otto, KL
    Garber, RL
    Quan, JM
    Montgomery, AB
    Albers, GM
    Ramsey, BW
    Smith, AL
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1999, 179 (05) : 1190 - 1196
  • [2] A reassessment of the in-vitro activity of colistin sulphomethate sodium
    Catchpole, CR
    Andrews, JM
    Brenwald, N
    Wise, R
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 39 (02) : 255 - 260
  • [3] In vitro activity of meropenem, imipenem, cefepime and ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients
    Christenson, JC
    Korgenski, EK
    Daly, JA
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 45 (06) : 899 - 901
  • [4] *COM ANT SOC FRANC, 2001, COMM 2000 2001, P30
  • [5] Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis:: a European consensus
    Döring, G
    Conway, SP
    Heijerman, HGM
    Hodson, ME
    Hoiby, N
    Smyth, A
    Touw, DJ
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2000, 16 (04) : 749 - 767
  • [6] *DTSCH I NORM EV, 2000, 58940 DIN EV
  • [7] Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: Review of available interpretative criteria and quality control guidelines
    Gales, AC
    Reis, AO
    Jones, RN
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (01) : 183 - 190
  • [8] COLISTIN INHALATION-THERAPY IN CYSTIC-FIBROSIS PATIENTS WITH CHRONIC PSEUDOMONAS-AERUGINOSA LUNG INFECTION
    JENSEN, T
    PEDERSEN, SS
    GARNE, S
    HEILMANN, C
    HOIBY, N
    KOCH, C
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1987, 19 (06) : 831 - 838
  • [9] In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis
    Li, J
    Turnidge, J
    Milne, R
    Nation, RL
    Coulthard, K
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (03) : 781 - 785
  • [10] NEBULIZED COLOMYCIN FOR EARLY PSEUDOMONAS COLONIZATION IN CYSTIC-FIBROSIS
    LITTLEWOOD, JM
    MILLER, MG
    GHONEIM, AT
    RAMSDEN, CH
    [J]. LANCET, 1985, 1 (8433) : 865 - 865